Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study - Innovaderm Research

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Test

Post navigation

Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis.

Incidence of Cardiovascular Events Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Pooled Data from 3 Large Randomised Clinical Trials

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

CRO Services
Participate In a Study
About Us
Careers
Contact
FR

Dermatology Clinic
3530 Saint-Laurent boulevard
Suite 400
Montreal, QC, H2X 2V1, Canada

© Innovaderm 2025. All rights reserved.